Methyl 4-(Butyrylamino)-3-Methyl-5-Nitrobenzoate CAS 152628-01-8 Kemurnian >99,0% (HPLC) Telmisartan Intermediate Factory
Pasokan Kimia Ruifu Telmisartan Intermediet Kanthi Kemurnian Dhuwur
Telmisartan CAS 144701-48-4
Metil 2-(p-Tolyl)benzoat CAS 114772-34-8
2-(p-Tolyl)Asam benzoat CAS 7148-03-0
Telmisartan Benzimidazole Asam CAS 152628-03-0
Telmisartan Methyl Ester CAS 528560-93-2
Metil 2-[4-(Bromomethyl)fenil]benzoat CAS 114772-38-2
Metil 4-(Butyrylamino)-3-Metil-5-Nitrobenzoate CAS 152628-01-8
2-n-Propil-4-Metil-6-(1-Metilbenzimidazol-2-yl)benzimidazol CAS 152628-02-9
Jeneng Kimia | Metil 4-(Butyrylamino)-3-Metil-5-Nitrobenzoate |
sinonim | Telmisartan Impurity 31;3-Metil-4-Butyrylamido-5-Nitro Asam Benzoat Metil Ester;4-Butyrylamino-3-metil-5-nitrobenzoic Asam Metil Ester |
Nomer CAS | 152628-01-8 |
Nomer CAT | RF-PI1881 |
Status Simpenan | Ing Simpenan, Skala Produksi Nganti Ton |
Formula Molekul | C13H16N2O5 |
Bobot Molekul | 280.28 |
Titik Lebur | 151.0~153.0 ℃ |
Kapadhetan | 1.265 |
Merk | Kimia Ruifu |
Item | Spesifikasi |
Penampilan | Bubuk Putih |
Kemurnian / Metode Analisis | > 99,0% (HPLC) |
Mundhut ing Pangatusan | <1.00% |
Sisa ing Ignition | <0,50% |
Total Impurities | <1.00% |
Logam Berat (Pb) | <20 ppm |
Test Standar | Standar Perusahaan |
Panggunaan | Penengah Telmisartan (CAS: 144701-48-4) |
Paket: Botol, tas Aluminium foil, 25kg / Karton Drum, utawa miturut kabutuhan pelanggan
Kondisi panyimpenan:Simpen ing wadhah sing disegel ing papan sing adhem lan garing;Nglindhungi saka cahya lan Kelembapan
Methyl 4-(Butyrylamino)-3-Methyl-5-Nitrobenzoate (CAS: 152628-01-8) minangka perantara sintetik sing migunani ing produksi Telmisartan (CAS: 144701-48-4), obat antihipertensi.Methyl 4-(Butyrylamino)-3-Methyl-5-Nitrobenzoate minangka bagean saka proses sintesis Telmisartan sing luwih efisien babagan impurity, ngasilake, biaya, lan produksi skala gedhe.Telmisartan minangka blocker reseptor angiotensin II (ARB) sing dituduhake kanggo: Perawatan hipertensi, kanggo nyuda tekanan getih.Ngurangi tekanan getih nyuda risiko kedadeyan kardiovaskular sing fatal lan nonfatal, utamane stroke lan infark miokard.Ngurangi risiko kardiovaskular (CV) ing pasien sing ora bisa njupuk inhibitor ACE.